Ourmanufacturing site Burlington, Ontario
Invested $30 million building a state-of-the-art GMP solid dose manufacturing and R&D facility
- Canadian pharmaceutical manufacturing facility with a Drug Establishment License (DEL) dedicated to the development of cannabinoid based pharmaceutical products requiring full GMP manufacturing capabilities.
- Designed, constructed, and qualified for efficiency and high-capacity output
- Environmental conditions (temperature, humidity, differential pressure) are monitored continuously by the Building Automation System (BAS)